clinical trial · NCT07723534
Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers
Midhun Malla·phase2·not yet recruiting·n = 32
Advanced Biliary Tract CancerMetastatic Biliary Tract CarcinomaZolbetuximabmFOLFOX6CAPOX
brief summary
Subjects will receive zolbetuximab with either CAPOX every 3 weeks or mFOLFOX6 every 2 weeks. The chemotherapy regimen chosen, mFOLFOX6 or CAPOX is per the treating investigator discretion and subject preference. Study treatment will continue for a maximum of 2 years, or until disease progression per RECIST 1.1, intolerable side effects, or investigator/subject preference. Disease evaluation will occur every 8 to 9 weeks.
started
Aug 1, 2026
primary completion
Feb 1, 2029
completion
Aug 1, 2030
last updated
Jul 23, 2026
official title
A Single Arm Phase II Trial of Zolbetuximab in Combination With mFOLFOX6 or CAPOX Chemotherapy in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol